Abstract
Background Cancers often overexpress multiple clinically relevant oncogenes. However, it is not known if multiple oncogenes within a cancer combine uniquely in specific cellular sub-populations to influence clinical outcome. We studied this phenomenon using the prognostically relevant oncogenes MYC, BCL2 and BCL6 in Diffuse Large B-Cell Lymphoma (DLBCL).
Methods Quantitative multispectral imaging simultaneously measured oncogene co-expression at single-cell resolution in reactive lymphoid tissue (n=12) and four independent cohorts (n=409) of DLBCL. Mathematically derived co-expression phenotypes were evaluated in DLBCLs with immunohistochemistry (n=316) and eight DLBCL cohorts with gene expression data (n=4186). Bulk and single-cell RNA sequencing was performed on patient-derived B-cells with induced co-expression of MYC, BCL2 and BCL6.
Results Unlike in non-malignant lymphoid tissue where the co-expression of MYC, BCL2 and BCL6 in a B-cell is limited, DLBCLs show multiple permutations of oncogenic co-expression in malignant B-cells. The percentage of cells with a unique combination MYC+BCL2+BCL6-(M+2+6-) consistently predicts survival in contrast to that of other combinations (including M+2+6+). An estimated percentage of M+2+6-cells can be derived from any quantitative measurement of the component individual oncogenes, and correlates with survival in immunohistochemistry and gene expression datasets. Comparative transcriptomic analysis of DLBCLs and transformed patient-derived B-cells identifies cyclin D2 (CCND2) as a potential BCL6-repressed regulator of proliferation in the M+2+6-population.
Conclusions Unique patterns of oncogene co-expression at single-cell resolution affect clinical outcomes in DLBCL. Similar analyses evaluating oncogenic combinations at the cellular level may impact diagnostics and target discovery in other cancers.
Competing Interest Statement
ADJ has received consultancy fees from Turbine Ltd, AstraZeneca, Antengene, Janssen MSD and IQVIA; travel funding from Perkin Elmer; and research funding from Janssen and AstraZeneca The other co-authors have no relevant conflicts of interest to declare.
Funding Statement
ADJ was supported by the Singapore Ministry of Health National Medical Research Council Transition Award (NMRC/TA/0052/2016). Work in ADJ laboratory is funded by a core grant from the Cancer Science Institute of Singapore, National University of Singapore through the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative, as well as by Singapore Ministry of Health National Medical Research Council 'Singapore lYMPHoma translatiONal studY (SYMPHONY)' Open Fund Large Collaborative Grant (MOH-000205-03). CT was supported by the Italian Foundation for Cancer Research (AIRC) Investigator Grant IG ID.22145; 5x1000 Grant ID.22759. The work in DJH lab was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. D.J.H. was supported by a fellowship from Cancer Research UK (CRUK) (RCCFEL∖100072) and received core funding from Wellcome (203151/Z/16/Z) to the Wellcome-MRC Cambridge Stem Cell Institute and from the CRUK Cambridge Centre (A25117). For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of patient samples from National University Hospital, Singapore, was approved by the Singapore NHG Domain Specific Review Board B study protocol (2015/00176). Relevant ethics approvals from all providing institutions were incorporated into the framework of an NUS IRB approved translational study (H-19-055E).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This manuscript has been significantly revised and now includes: a spatial analysis evaluating the clustering patterns of the 8 MYC/BCL2/BCL6 co-expressing sub-populations; a prognostic evaluation of the M+2+6- subpopulation across additional validation cohorts; and a molecular analysis of the M+2+6- subpopulation.
Data Availability
RNAseq data is deposited to GEO (https://www.ncbi.nlm.nih.gov/geo/) under the access number: GSE203446. Requests for primary image data/protocols can be made to Dr Anand Jeyasekharan via email: csiadj{at}nus.edu.sg.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203446
